Cancer Diagnostics – Multimedia
Automated Nucleic Acid Sample QC in NGS Workflows
At various points throughout the NGS workflow, QC steps are recommended to avoid time and resource wasting, and to help prevent suboptimal sequencing data.
Change the Landscape of Cancer Detection and Treatment With Liquid Biopsies
Download this infographic to learn about the importance of liquid biopsies and their use in cancer diagnosis and monitoring.
In this infographic, we delve into the field of cancer genetics, highlight key milestones and explore how genomic approaches are transforming diagnosis and treatment of the disease in the clinic.
Methylation Sequencing in Cancer Detection
Download this eBook to learn more about the impact of methylation and epigenetics in cancer.
Agents of Change: Tracking Tumor Progression With MALDI Imaging of Glycans
Researchers at the Bruker-MUSC Clinical Glycomics Center of Excellence are developing and applying new technologies to map glycans in tissue and classify changes that occur during development of cancer.
What Agilent Sample Quality Metrics are Available?
Agilent sample quality metrics are available for most RNA and DNA samples used in NGS, enabling you to know the concentration, size and integrity of your nucleic acid fragments.
A Blood Test for Cancer
Since many cancers don’t have symptoms early on, they may go unnoticed until they are at an advanced stage. But that is changing, thanks to a newer, non-invasive tool.
What Is New in Disease Biomarker Discovery?
Download this listicle to explore various biomarkers, technological advances driving biomarker research and integrative approaches in disease research.
Assessing the Quality and Quantity of Cell-Free DNA
For circulating cell free DNA (ccfDNA) to be used in cancer research successfully, workflow standardization is essential. Access this poster to discover tips on optimal workflow control, how to yield smaller ccfDNA fragments and the differences in quantification and qualification of ccfDNA.
DNA in Urine for Liquid Biopsy of Cancer
Urinalysis has long been a staple of physical exams to detect and manage a number of diseases and disorders, but not cancer. What if it were that easy, though, and cancer was detected in its very earliest stages when the disease responds more favorably to treatment and improved outcomes are more likely?